Q BioMed Inc

Full interview: Q BioMed successfully synthesizes molecule to treat liver cancer in a 'tremendously exciting achievement'

Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive that the New York-based biotech, together with India-based research organization Chemveda Life Sciences, has made a breakthrough with its therapy as a potential chemotherapy to treat liver cancer.

Corin says the molecule called Uttroside-B, is in pre-clinical development, and the company looks forward to submit it as an investigational new drug in 1Q of 2020.

Quick facts: Q BioMed Inc

Price: $0.83

Market: OTCQB
Market Cap: $12.23 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc named herein, including the promotion by the Company of Q BioMed Inc in any Content on the Site, the Company receives from said...



Q BioMed discovers two key biomarkers in study of pediatric nonverbal autism

Q BioMed Inc (OTCMKTS:QBIO) CEO Denis Corin tells Proactive Investors the New York-based biotech has made a "tremendous" discovery in the first two biomarkers for pediatric nonverbal autism. Corin says this allows the company a greater chance of success in its clinical study for drug...

on 04/11/2019

2 min read